RLAY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
350.0K
-88.3%
3.0M
-57.1%
7.0M
0
-100.0%
677.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
350.0K
-88.3%
3.0M
-57.1%
7.0M
0
-100.0%
677.0K
Operating Expenses
91.2M
+11.7%
81.6M
+20.7%
67.6M
-15.9%
80.4M
+3.7%
77.5M
R&D
76.5M
+8.4%
70.6M
+27.3%
55.4M
-18.8%
68.3M
+6.8%
63.9M
SG&A
14.7M
+33.2%
11.0M
-9.7%
12.2M
+0.7%
12.1M
-11.0%
13.6M
Operating Income
-90824000
-15.5%
-78643000
-29.7%
-60630000
+24.6%
-80391000
-4.6%
-76847000
EBITDA
-90464000
-15.8%
-78139000
-30.2%
-60031000
+24.6%
-79643000
-5.0%
-75845000
Net Income
-83707000
-14.2%
-73291000
-33.5%
-54890000
+26.0%
-74149000
-5.4%
-70375000
EPS (Basic)
$-0.41
+0.0%
$-0.41
-28.1%
$-0.32
+25.6%
$-0.43
-4.9%
$-0.41
EPS (Diluted)
$-0.41
+0.0%
$-0.41
-28.1%
$-0.32
+25.6%
$-0.43
-4.9%
$-0.41
Shares (Diluted)
202.8M
+12.8%
179.8M
+3.7%
173.5M
+0.6%
172.4M
+0.7%
171.3M
Relay Therapeutics (RLAY) โ€” Financials